LPH 5
Alternative Names: LPH-5Latest Information Update: 13 Dec 2024
Price :
$50 *
At a glance
- Originator Lophora
- Developer Beckley Psytech; Lophora
- Class Antidepressants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Major depressive disorder
Most Recent Events
- 09 Dec 2024 Lophora plans phase I pharmacokinetics trial in healthy volunteers in April 2025 (NCT06722820)
- 11 May 2022 Lophora plans to submit IND application for LPH 5 in Major depressive disorder in the first quarter of 2023
- 11 May 2022 Lophora plans clinical trials in Major depressive disorder (treatment-resistant depression) in 2023